Norsland: Subsidiary hydroxymethylzine hydrochloride eye drops approved for clinical trials.

Notice from Northland: The subsidiary Beijing Hui'enlan Pharmaceutical Co., Ltd. has obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its hydroxyamodine eye drops. The product specification is 0.1%, the indication is for the treatment of adult acquired ptosis of the upper eyelid, and the application is for Phase III clinical trials. The approval conclusion is to proceed with the clinical trials. The company will strictly comply with national clinical trial requirements, submit relevant data and apply for production and marketing approval after the work is completed. Short-term performance will not be significantly affected until approval is obtained for market launch.